A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630).
- Chipman, Mitchell (Primary Chief Investigator (PCI))
- Hawkins, Cheryl-Ann, (Project Manager)
- Cross, Nikki, (Project Manager)
Project: Research